Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05361798RecruitingPhase 2
Testing immune response after prostate radiation with or without a drug
This study checks how your immune system’s cancer-fighting cells change after stereotactic body radiation (SBRT) to the prostate. It compares SBRT alone versus SBRT plus an immunotherapy drug (PDS01ADC) in men with intermediate- or high-risk localized prostate cancer treated with hormone therapy (ADT).
Bethesda, MarylandAges 18 years+ - NCT02381990Recruiting
MRI- and ultrasound-guided freezing treatment for low-risk prostate cancer
This trial tests using MRI and ultrasound together to guide freezing (cryoablation) treatment for prostate cancer. It may help target the tumor more precisely while avoiding areas that could cause side effects.
Miami Lakes, FloridaAges 55 years+ - NCT06990880RecruitingPhase 1/Phase 2
A study of a new drug for advanced prostate cancer
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
Phoenix, ArizonaAges 18 years+ - NCT02391051RecruitingPhase 2
Targeted radiation for low-risk prostate cancer
This trial tests a focused form of radiation placed inside the prostate to treat only the cancer area in people with low-risk prostate cancer. It aims to control the cancer while limiting treatment to a smaller area.
ErlangenAges 18 years+ - NCT01194648Recruiting
HIFU treatment for early prostate cancer
This trial studies a focused ultrasound treatment called HIFU for prostate cancer that appears limited to the early stages. It aims to treat cancer within the prostate while avoiding treatment spread to lymph nodes or distant organs.
London, EnglandAges Up to 90 years - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT07672119Recruiting
Heart risks in older men on enzalutamide or darolutamide
This study looks at heart-related risks in older men with advanced prostate cancer who are taking enzalutamide or darolutamide. It may help doctors better understand how to manage heart health during treatment.
Whippany, New JerseyAges 55 years+ - NCT06665932Recruiting
Stereotactic radiotherapy for prostate cancer with smaller margins
This trial tests a precise radiation treatment for prostate cancer that uses smaller safety margins to reduce side effects while still targeting the cancer effectively. It may be a good option for people with early-stage, low- or favorable intermediate-risk prostate cancer.
Ostrava, Moravian-Silesian RegionAges 18 years+ - NCT07594002Recruiting
Acupuncture for hot flashes in prostate cancer patients
This study tests whether real acupuncture works better than fake acupuncture for reducing hot flashes (sudden episodes of intense heat and sweating) in men with prostate cancer who are on hormone therapy. If acupuncture helps, it could offer relief without more medications.
Lexington, KentuckyAges 18–99 - NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90 - NCT07474142Recruiting
PSMA PET scan for newly diagnosed prostate cancer
This study looks at whether a special scan called PSMA PET can help predict how prostate cancer will progress. It is for people who have just been diagnosed and have not started treatment yet.
Lanzhou, GansuAges 18–100 - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80 - NCT07300566Recruiting
Focal versus whole-gland radiation boost for localized prostate cancer
This trial compares two ways of giving a radiation boost (brachytherapy) to the prostate for men with localized prostate cancer. One method targets only the visible tumor, while the other treats the whole gland, and the study aims to see if the focal approach works as well with fewer side effects.
London, OntarioAges 18 years+ - NCT07266129Recruiting
Virtual biopsy for prostate cancer using PSMA PET and AI
This trial uses a special PET scan (PSMA PET) and artificial intelligence to see if we can detect prostate cancer without a needle biopsy. It is for men who are either already scheduled for a PET scan or who have symptoms or high PSA suggesting prostate cancer.
Tromsø, TromsAges Any age - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07190300RecruitingPhase 1/Phase 2
Study of tulmimetostat plus other hormone therapies for metastatic prostate cancer
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
Birmingham, AlabamaAges 18 years+ - NCT06949254Recruiting
Study of radiation and hormone therapy for high-risk prostate cancer
This study looks at combining stereotactic body radiation therapy (a precise type of radiation) with hormone therapy for men with high-risk prostate cancer that hasn't spread. The goal is to see how well this treatment works with fewer side effects.
Bergamo, BergamoAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT06607783Recruiting
Prostate cancer detection with smarter MRI calibration
This trial tests a new calibration technology to improve how suspicious spots seen on MRI are targeted during prostate biopsy. It may help men who need a biopsy after an MRI shows a possible cancer area (Likert 3 or higher).
London, LondonAges 18 years+ - NCT06615752RecruitingPhase 1/Phase 2
Green tea and quercetin with chemo for prostate cancer
This trial tests whether adding green tea extract and quercetin (a plant compound) to standard chemotherapy (docetaxel) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination is safe and works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT06172283Recruiting
Intermittent fasting with hormone therapy for prostate cancer
This trial tests whether intermittent fasting (alternating between eating and not eating for certain periods) can help men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). It aims to see if fasting during treatment can reduce side effects or improve how well the therapy works.
Buffalo, New YorkAges 18 years+ - NCT06130995RecruitingPhase 1
Relugolix and enzalutamide for high-risk prostate cancer
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Oklahoma City, OklahomaAges 18 years+ - NCT05520255RecruitingPhase 3
PSMA PET/CT scan to guide care after prostate cancer treatment
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
Edmonton, AlbertaAges 18 years+
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.